Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| Immunostimulants drugs | 7 | 0.72 [0.37; 1.43], 2 RCTs, I2=58% demonstrated
inconclusive result | 0.68 [0.21; 2.20], 1 RCT, I2=0%
inconclusive result | 0.78 [0.58; 1.05], 6 RCTs, I2=0%
inconclusive result | 1.61 [0.61; 4.25], 3 RCTs, I2=82%
inconclusive result | |
| Immunosuppressants drugs | 6 | 0.53 [0.22; 1.28], 2 RCTs, I2=78% demonstrated
inconclusive result | 1.39 [0.76; 2.54], 1 RCT, I2=0%
inconclusive result | 0.68 [0.48; 0.97], 5 RCTs, I2=0%
moderate degree of certainty | - | |
| anti-inflammatory therapies | 4 | 0.12 [0.01; 1.91], 2 RCTs, I2=69%
inconclusive result | - | 0.42 [0.04; 4.91], 2 RCTs, I2=0%
inconclusive result | 1.71 [0.80; 3.64], 1 RCT, I2=0%
inconclusive result | |
| Kinase inhibitors | 1 | - | - | - | - | |
| Apilimod | 0 | - | - | - | - | |
| corticosteroids | 0 | - | - | - | - | |
| inhaled corticosteroids | 0 | - | - | - | - | |
| leflunomide | 0 | - | - | - | - | |
| meplazumab | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| statins | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
